2-232336580-A-G
Variant summary
Our verdict is Likely benign. Variant got -2 ACMG points: 2P and 4B. PM2BP4_Strong
The NM_152383.5(DIS3L2):āc.2608A>Gā(p.Lys870Glu) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000603 in 1,608,770 control chromosomes in the GnomAD database, including 1 homozygotes. In-silico tool predicts a benign outcome for this variant. 15/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (ā ā ).
Frequency
Consequence
NM_152383.5 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -2 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
DIS3L2 | NM_152383.5 | c.2608A>G | p.Lys870Glu | missense_variant | 21/21 | ENST00000325385.12 | NP_689596.4 | |
DIS3L2 | NM_001257281.2 | c.1582-6765A>G | intron_variant | NP_001244210.1 | ||||
DIS3L2 | NR_046476.2 | n.2681A>G | non_coding_transcript_exon_variant | 21/21 | ||||
DIS3L2 | NR_046477.2 | n.3254A>G | non_coding_transcript_exon_variant | 19/19 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
DIS3L2 | ENST00000325385.12 | c.2608A>G | p.Lys870Glu | missense_variant | 21/21 | 5 | NM_152383.5 | ENSP00000315569 | P1 |
Frequencies
GnomAD3 genomes AF: 0.0000922 AC: 14AN: 151912Hom.: 0 Cov.: 33
GnomAD3 exomes AF: 0.000115 AC: 28AN: 243444Hom.: 0 AF XY: 0.000150 AC XY: 20AN XY: 133172
GnomAD4 exome AF: 0.0000570 AC: 83AN: 1456858Hom.: 1 Cov.: 31 AF XY: 0.0000717 AC XY: 52AN XY: 724954
GnomAD4 genome AF: 0.0000922 AC: 14AN: 151912Hom.: 0 Cov.: 33 AF XY: 0.0000674 AC XY: 5AN XY: 74212
ClinVar
Submissions by phenotype
Perlman syndrome Uncertain:2
Uncertain significance, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Oct 31, 2018 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 02, 2024 | This sequence change replaces lysine, which is basic and polar, with glutamic acid, which is acidic and polar, at codon 870 of the DIS3L2 protein (p.Lys870Glu). This variant is present in population databases (rs775252407, gnomAD 0.04%). This variant has not been reported in the literature in individuals affected with DIS3L2-related conditions. ClinVar contains an entry for this variant (Variation ID: 463111). Experimental studies and prediction algorithms are not available or were not evaluated, and the functional significance of this variant is currently unknown. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
not specified Uncertain:1
Uncertain significance, no assertion criteria provided | clinical testing | Genetic Services Laboratory, University of Chicago | Dec 15, 2022 | DNA sequence analysis of the DIS3L2 gene demonstrated a sequence change, c.2608A>G, in exon 21 that results in an amino acid change, p.Lys870Glu. This sequence change does not appear to have been previously described in individuals with DIS3L2-related disorders. This sequence change has been described in the gnomAD database with a frequency of 0.012% in the overall population (dbSNP rs775252407). The p.Lys870Glu change affects a poorly conserved amino acid residue located in a domain of the DIS3L2 protein that is not known to be functional. The p.Lys870Glu substitution appears to be benign using several in-silico pathogenicity prediction tools (SIFT, PolyPhen2, Align GVGD, REVEL). Due to insufficient evidences and the lack of functional studies, the clinical significance of the p.Lys870Glu change remains unknown at this time. - |
Inborn genetic diseases Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Jun 28, 2022 | The c.2608A>G (p.K870E) alteration is located in exon 21 (coding exon 20) of the DIS3L2 gene. This alteration results from a A to G substitution at nucleotide position 2608, causing the lysine (K) at amino acid position 870 to be replaced by a glutamic acid (E). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
not provided Uncertain:1
Uncertain significance, criteria provided, single submitter | not provided | Breakthrough Genomics, Breakthrough Genomics | - | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at